EGFR and non-small cell lung carcinoma: According to this, our results suggested that NSCLC co‐express the α‐ and β‐ isoforms of ATG16‐L1 that differ by the retention of exon 8 in the β‐ isoform only, and that cells with acquired resistance to EGFR‐TKI overexpress the ATG16‐L1 β‐isoform.